Rutan Cipinang
Jakarta Pusat, West Java, Indonesia
NCT Number: NCT04155320
Researchers will conduct a 2-arm pilot randomized controlled trial with HIV-infected index patients recruited from two all-male prisons in Indonesia to assess the acceptability and feasibility of provider-assisted HIV partner notification (provider referral) and examine its potential to increase the number of partners who are tested for HIV and subsequently linked to prevention and treatment services.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Jakarta Pusat, West Java, Indonesia
This study compares three options for partner notification:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for HIV-positive Prisoners (N=65): Index patients must beat least 18 years of age, HIV-seropositive and aware of their HIV+ status; (HIV-infection documented by a rapid HIV test); sexually active and/or sharing needles in the 12 months before incarceration; incarcerated within the past 3 years and ≥6 months of their prison sentence remaining. We will limit enrollment to index patients who are willing to notify partners and have 1 or more partner(s) who have not yet been notified.
Inclusion criteria
for Partners: Eligible partners will be persons who participants (index patients) are able to identify by first and/or last name, residential address and/or mobile phone number, and physical descriptors (e.g., approximate height) and have given nurses permission to contact. No named partner will be excluded on the basis of religion, ethnicity, age, sex, or gender identity.
Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.
Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
Time frame: 6 weeks from index patient enrollment
Number of partners who are notified of shared HIV exposure
Time frame: 6 weeks from index patient enrollment
Number of partners who receive HIV testing subsequent to notification
Time frame: 6 weeks from index patient enrollment
Number of partners who are HIV diagnosed subsequent to testing
Time frame: 6 weeks from index patient enrollment
Number of partners who have been evaluated for treatment by a physician subsequent to diagnosis
Time frame: 6 weeks from index patient enrollment
Number of partners who have initiated antiretroviral therapy (ART) subsequent to linkage to care
University of Illinois at Chicago
Other
Provider-Assisted HIV Partner Notification & Testing With Prisoners in Indonesia: A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05388474
Blood-Borne Infections, Communicable Diseases
Los Angeles, California, United States
View Trial DetailsNCT03284710
Blood-Borne Infections, Communicable Diseases
Maputo, Mozambique
View Trial DetailsNCT02591420
Blood-Borne Infections, Communicable Diseases
Kericho, Kenya
View Trial DetailsNCT02447159
Behavior, Blood-Borne Infections
Eket, Akwa Ibom State, Nigeria
View Trial Details